Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Sex on Cardiovascular Adaptations to Exercise: JACC Review Topic of the Week.
Petek BJ, Chung EH, Kim JH, Lampert R, Levine BD, Phelan D, Danielian A, Dean PN, Dineen EH, Fernandez AB, Husaini M, Krishnan S, Shah AB, Stewart KM, Wasfy MM. Petek BJ, et al. Among authors: dineen eh. J Am Coll Cardiol. 2023 Sep 5;82(10):1030-1038. doi: 10.1016/j.jacc.2023.05.070. J Am Coll Cardiol. 2023. PMID: 37648352 Review.
Quantification of Prostate Cancer Metabolism Using 3D Multiecho bSSFP and Hyperpolarized [1-13 C] Pyruvate: Metabolism Differs Between Tumors of the Same Gleason Grade.
Chowdhury R, Mueller CA, Smith L, Gong F, Papoutsaki MV, Rogers H, Syer T, Singh S, Brembilla G, Retter A, Bullock M, Caselton L, Mathew M, Dineen E, Parry T, Hennig J, von Elverfeldt D, Schmidt AB, Hövener JB, Emberton M, Atkinson D, Bainbridge A, Gadian DG, Punwani S. Chowdhury R, et al. Among authors: dineen e. J Magn Reson Imaging. 2023 Jun;57(6):1865-1875. doi: 10.1002/jmri.28467. Epub 2022 Oct 31. J Magn Reson Imaging. 2023. PMID: 36315000 Free PMC article.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550261 Free PMC article. Clinical Trial.
25 results